TIGIT and plasma cell myeloma: In MM patients, especially those with relapsed/refractory MM (RRMM), co-inhibitory molecules including PD-1 and TIGIT are upregulated on activated T-cells, which protects myeloma cells from immune attack by directly interacting with their ligand expressed in myeloma cells (55–57).